Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...

Alzheimer Disease ll: Pathophysiology

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Mitochondrial dysfunction in peripheral mononuclear blood cells (PBMC) of individuals with mild cognitive impairment.

GeroScience·2025

Same author

Simvastatin as Add-On Treatment to Escitalopram in Patients With Major Depression and Obesity: A Randomized Clinical Trial.

JAMA psychiatry·2025

Same author

The temporal organization and quality of life story memories in Alzheimer disease and healthy controls.

Neuropsychology·2025

Same author

[Multi-professional Clearing in a Model Project based on § 64b SGB V by the Example of Geriatric Psychiatry].

Psychiatrische Praxis·2025

Same author

Correction: Lithium Therapy in Old Age: Recommendations from a Delphi Survey.

Pharmacopsychiatry·2023

Same author

Lithium Therapy in Old Age: Recommendations from a Delphi Survey.

Pharmacopsychiatry·2023

Search research articles

Related Experiment Video

Updated: May 25, 2026

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Published on: November 9, 2018

Treatment options for tauopathies.

Tarik Karakaya¹, Fabian Fußer, David Prvulovic

¹Department of Psychiatry, J.W. Goethe-University, Heinrich-Hoffmann-Str. 10, 60528, Frankfurt, Germany, tarik.karakaya@kgu.de.

Current Treatment Options in Neurology

|February 7, 2012

Summary

This summary is machine-generated.

Currently, no approved treatments exist for tauopathies like progressive supranuclear palsy (PSP), frontotemporal dementia (FTD), and corticobasal degeneration (CBD). Research is exploring tau protein pathology as a promising therapeutic target.

More Related Videos

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

An In Vitro Model for Studying Tau Aggregation Using Lentiviral-mediated Transduction of Human Neurons

An In Vitro Model for Studying Tau Aggregation Using Lentiviral-mediated Transduction of Human Neurons

Published on: May 23, 2019

Related Experiment Videos

Last Updated: May 25, 2026

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Published on: November 9, 2018

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

An In Vitro Model for Studying Tau Aggregation Using Lentiviral-mediated Transduction of Human Neurons

An In Vitro Model for Studying Tau Aggregation Using Lentiviral-mediated Transduction of Human Neurons

Published on: May 23, 2019

Area of Science:

Neuroscience
Neurology
Pharmacology

Background:

Tauopathies, including progressive supranuclear palsy (PSP), frontotemporal dementia (FTD), and corticobasal degeneration (CBD), are heterogeneous neuropsychiatric disorders often presenting as atypical Parkinson syndromes.
Currently, no pharmacologic treatments are approved for tauopathies, with existing strategies relying on limited evidence from small trials and case reports, often yielding contradictory results.

Purpose of the Study:

To review current treatment strategies for tauopathies.
To highlight the limitations of existing therapies and the need for novel approaches targeting the underlying disease mechanisms.

Main Methods:

Review of available literature on pharmacologic and non-pharmacologic interventions for tauopathies.
Analysis of off-label use of medications approved for Alzheimer's dementia and Parkinson's disease.
Discussion of symptomatic treatments for cognitive, behavioral, and motor symptoms.

Main Results:

Off-label use of acetylcholinesterase inhibitors and memantine for cognitive symptoms in tauopathies shows inconsistent outcomes.
Levodopa and dopamine agonists are used for motor symptoms, while selective serotonin reuptake inhibitors may help with behavioral issues.
Antipsychotics carry significant risks and should be used cautiously due to adverse effects and increased cerebrovascular event risk in tauopathies.

Conclusions:

Current treatment for tauopathies is largely symptomatic and individualized, with no therapies targeting the disease's root cause.
Physical, occupational, and speech therapies can improve functional abilities.
Emerging research focusing on tau protein pathology, such as aggregation and phosphorylation, shows promise for future therapeutic development.